Theralase Technologies Inc. V.TLT

Alternate Symbol(s): TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc. > FDA Approval for TLD1433 pdt almost certain IMHO

<< Previous

Bullboard Posts

Next >>

Comment by Kingpin68on Jan 26, 2023 7:57pm

265 Views

Post# 35249166

RE:FDA Approval for TLD1433 pdt almost certain IMHO

Eog, what do you make of the wording here : 'Of the patients who achieved an initial CR, 46% (n=23 of 50) continued to remain free of high-grade recurrence at 12 months.'

Why ' high grade recurrence '. Is low grade recurrence acceptable. And how does that compare to TLD's partial response numbers. Isn't a partial response the same or similar to being free of high-grade reoccurrence?

<< Previous

Bullboard Posts

Next >>

The top 10 Canadian medical stocks